CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

doi:10.1126/scitranslmed.adz3553

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

Science translational medicine - 1 Jul 2026

Rampotas Alexandros, Wong Zoë C, Gannon Isaac, Brierley Charlotte K, Shen Yuqi, Benlabiod Camelia, Chee Ashlyn, Khan Saif, Hayder Nawshad, Cheung Gordon Weng-Kit, Mitsikakou Marina, Murphy Eleanor, Ferrari Mathieu, Bulek Anna, Rodriguez-Romera Antonio, Murphy Lauren, Olijnik Aude-Anais, Rodriguez-Justo Manuel, Marty Caroline, Hitchcock Ian, Royston Daniel, Mead Adam J, Khan Abdullah O, Lambert Jonathan, Roddie Claire, Psaila Bethan, Pule Martin A

Abstract excerpt

Targeted immunotherapies have revolutionized outcomes for lymphoid malignancies, but success in myeloid neoplasms is limited by the lack of amenable targets and immunologically hostile tumor microenvironment (TME). Myeloproliferative neoplasms (MPNs) are chronic myeloid blood cancers, a third of which are driven by mutations in calreticulin. Calreticulin mutant protein (mutCALR) binds and activates thrombopoietin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Organoids

Share to Primary Myelofibrosis

Share to Receptors, Chimeric Antigen

Share to Receptors, Thrombopoietin

Share to T-Lymphocytes

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed

Identifiers

PMID: 42384776
DOI: 10.1126/scitranslmed.adz3553

Genes

CD34

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.PMID 42384776Read ↗

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosisSemantic proximity Read ↗

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN.Semantic proximity Read ↗

CAR-T Targeting of Mutant Calreticulin Establishes a Potentially Curative Stem Cell-Directed Therapy for Myeloproliferative NeoplasmsSemantic proximity Read ↗

Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.Semantic proximity Read ↗

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo.Semantic proximity Read ↗

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.Semantic proximity Read ↗

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.Semantic proximity Read ↗

Mutant Calreticulin in the Myeloproliferative NeoplasmsSemantic proximity Read ↗

Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.Semantic proximity Read ↗

Mutant calreticulin in myeloproliferative neoplasmsSemantic proximity Read ↗

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.Semantic proximity Read ↗

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.